ATE226446T1 - Muteine von wildtyp-cytokinen und ihre verwendung als immunogene - Google Patents

Muteine von wildtyp-cytokinen und ihre verwendung als immunogene

Info

Publication number
ATE226446T1
ATE226446T1 AT96930345T AT96930345T ATE226446T1 AT E226446 T1 ATE226446 T1 AT E226446T1 AT 96930345 T AT96930345 T AT 96930345T AT 96930345 T AT96930345 T AT 96930345T AT E226446 T1 ATE226446 T1 AT E226446T1
Authority
AT
Austria
Prior art keywords
cytokines
muteins
immunogens
wild
type cytokines
Prior art date
Application number
AT96930345T
Other languages
English (en)
Inventor
Gennaro Ciliberto
Rocco Savino
Riccardo Cortese
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE226446T1 publication Critical patent/ATE226446T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Noise Elimination (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96930345T 1995-09-01 1996-08-22 Muteine von wildtyp-cytokinen und ihre verwendung als immunogene ATE226446T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95RM000589A IT1277926B1 (it) 1995-09-01 1995-09-01 Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
PCT/IT1996/000164 WO1997009064A1 (en) 1995-09-01 1996-08-22 Use of muteins of wild-type cytokines as immunogens

Publications (1)

Publication Number Publication Date
ATE226446T1 true ATE226446T1 (de) 2002-11-15

Family

ID=11403544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930345T ATE226446T1 (de) 1995-09-01 1996-08-22 Muteine von wildtyp-cytokinen und ihre verwendung als immunogene

Country Status (17)

Country Link
US (1) US6706261B1 (de)
EP (1) EP0858345B1 (de)
JP (1) JP3157837B2 (de)
KR (1) KR100279539B1 (de)
CN (1) CN1138562C (de)
AT (1) ATE226446T1 (de)
AU (1) AU703300B2 (de)
CA (1) CA2229045C (de)
DE (1) DE69624498T2 (de)
DK (1) DK0858345T3 (de)
ES (1) ES2183007T3 (de)
HK (1) HK1015708A1 (de)
IT (1) IT1277926B1 (de)
MX (1) MX9801550A (de)
PT (1) PT858345E (de)
RU (1) RU2182014C2 (de)
WO (1) WO1997009064A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (en) * 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
FR2812813B1 (fr) * 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
IL161672A0 (en) * 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
FR2978964B1 (fr) 2011-08-09 2015-02-20 Conservatoire Nat Arts Composition vaccinale anti-il-6
WO2015024148A1 (zh) * 2013-08-23 2015-02-26 中国科学院微生物研究所 异源动物细胞因子突变体疫苗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US5338833A (en) * 1992-07-23 1994-08-16 The University Of North Carolina At Chapel Hill Carboxy terminal IL-6 muteins
IT1263022B (it) * 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
AU6961796A (en) 1995-09-12 1997-04-01 Chiron Corporation Improved interleukin-6 receptor antagonist

Also Published As

Publication number Publication date
PT858345E (pt) 2003-02-28
ES2183007T3 (es) 2003-03-16
ITRM950589A1 (it) 1997-03-01
DE69624498D1 (de) 2002-11-28
ITRM950589A0 (it) 1995-09-01
IT1277926B1 (it) 1997-11-12
KR100279539B1 (ko) 2001-02-01
JP3157837B2 (ja) 2001-04-16
CN1138562C (zh) 2004-02-18
AU6942896A (en) 1997-03-27
DK0858345T3 (da) 2003-02-24
US6706261B1 (en) 2004-03-16
HK1015708A1 (en) 1999-10-22
EP0858345B1 (de) 2002-10-23
EP0858345A1 (de) 1998-08-19
JPH10511111A (ja) 1998-10-27
KR19990044321A (ko) 1999-06-25
DE69624498T2 (de) 2003-06-18
RU2182014C2 (ru) 2002-05-10
MX9801550A (es) 1998-05-31
CN1198098A (zh) 1998-11-04
CA2229045C (en) 2005-10-25
CA2229045A1 (en) 1997-03-13
WO1997009064A1 (en) 1997-03-13
AU703300B2 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
DK0591281T3 (da) Immunogene forbindelser, der især har anticytokinvirkning, fremstillingsfremgangsmåde, farmaceutiske præparater samt kits,
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
BRPI0508455A (pt) muteìnas de interleucina-2 combinatórias
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
ES2149971T3 (es) Derivados 5-sustituidos del acido micofenolico.
DK0754176T3 (da) Hidtil ukendte carbamater og urinstoffer som modifikatorer for multidrugsresistens
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
ATE320814T1 (de) Verwendung von zinkhyaluronat gegen magengeschwür
ATE403714T1 (de) Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen
ATE249835T1 (de) Immunoregulator
ATE226446T1 (de) Muteine von wildtyp-cytokinen und ihre verwendung als immunogene
ES2058343T3 (es) Piridinas disubstituidas.
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
ATE420951T1 (de) Schützende epitope von adenylate-zyklase- hämolysin(ac-hly) und ihre verwendung zur behandlung oder verhütung von bordetella- infektionen
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
ATE94074T1 (de) Verwendung von somatostatin.
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.
TR200000916T2 (tr) İkameli piperidin türevleri.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0858345

Country of ref document: EP

REN Ceased due to non-payment of the annual fee